Therapeutic nuclear medicine: Theranostic radiopharmaceuticals for metastatic cancer -focusing on targeted alpha therapy (Co-lead, South-Eastern Norway Regional Health Authority Grant), SIMPLERAD (Co-lead WP4, funded by the European Union), Biodistribution and dosimetry in a phase 1 trial of 224-Ra-CaCO3 particles (funded by sponsor), Dose-effects for a novel 177-Lu based treatment of non-Hodgkin lymphoma (South-Eastern Norway Regional Health Authority Research Grant), Simulation tools and quantitative 90-Y PET/CT for Selective Internal Radiation Therapy (South-Eastern Norway Regional Health Authority Innovation Grant), Dosimetry-based treatment planning of 131-I therapy.
Other studies: Quantitative PET parameters as predictors for patient outcome (part of different lymphoma trials), radiomics investigations, novel PET tracers for multiple myeloma assessments, and various technical projects related to image reconstruction and analyses.
Cicone F, Gnesin S, Santo G, Stokke C, Bartolomei M, Cascini GL, Minniti G, Paganelli G, Verger A, Cremonesi M(2024) Do we need dosimetry for optimization of theranostics in CNS tumors? Neuro Oncol(in press) DOI 10.1093/neuonc/noae200, PubMed 39351795
Trøstheim M, Eikemo M(2024) Hyperalgesia in Patients With a History of Opioid Use Disorder: A Systematic Review and Meta-Analysis JAMA Psychiatry(in press) DOI 10.1001/jamapsychiatry.2024.2176, PubMed 39141367
Thunold S, Hernes E, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Mikalsen LTG, Helland Å, Malinen E, Haakensen VD(2024) Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine Eur J Nucl Med Mol Imaging(in press) DOI 10.1007/s00259-024-06853-0, PubMed 39133306
Get in touch
Contact information Group Leader Caroline Stokke, PhD, Assoc. Prof., Department of Physics and Computational Radiology, carsto@ous-hf.no, (0047) 98685214